NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News → Urgent Nvidia Warning (From Altimetry) (Ad) Free PPH Stock Alerts $87.11 -0.30 (-0.34%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$86.76▼$87.6650-Day Range$84.87▼$90.8952-Week Range$74.05▼$91.16Volume111,102 shsAverage Volume140,129 shsMarket Capitalization$500.01 millionAssets Under Management$518.70 millionDividend Yield1.79%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media Get VanEck Pharmaceutical ETF alerts: Email Address About VanEck Pharmaceutical ETF (NASDAQ:PPH)The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.Read More PPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPH ETF News HeadlinesApril 23, 2024 | seekingalpha.comPPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total ReturnsApril 18, 2024 | theglobeandmail.comCanada’s updated guidance on ESG-related investment fund disclosureMay 4, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.April 3, 2024 | msn.comVanEck Pharmaceutical ETF declares quarterly distribution of $0.5328April 1, 2024 | msn.comVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.5328March 7, 2024 | investorplace.comThe Top 3 ETFs to Buy in March 2024February 28, 2024 | markets.businessinsider.com11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher YieldsFebruary 28, 2024 | stocknews.comNavigate to Success With These 4 Pharma Stocks to BuyMay 4, 2024 | Allegiance Gold (Ad)Could Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.February 26, 2024 | investorplace.comThe 3 Hottest Healthcare ETFs to Buy in 2024See More Headlines Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings26 Fund Statistics Assets Under Management$518.70 million Average Daily Volume$165,114.10 Discount/Premium0.06% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume7 Put Options3 Call Options4 Short Interest1,400,000 shs Miscellaneous Outstanding Shares5,740,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.34%0.58%Total Expense0.35%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%Net Expense0.35%0.60%0.60%0.54%0.58% VanEck Pharmaceutical ETF (PPH) Holdings & ExposureTop 10 PPH HoldingsEli Lilly and Company(NYSE:LLY)Holding Weight: 12.05%Novo Nordisk A/S(NYSE:NVO)Holding Weight: 9.70%Johnson & Johnson(NYSE:JNJ)Holding Weight: 6.48%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 6.28%AbbVie(NYSE:ABBV)Holding Weight: 5.81%AstraZeneca(NASDAQ:AZN)Holding Weight: 5.51%Cencora(NYSE:COR)Holding Weight: 4.81%Novartis AG ADRHolding Weight: 4.81%McKesson(NYSE:MCK)Holding Weight: 4.74%Haleon(NYSE:HLN)Holding Weight: 4.60%PPH Sector ExposurePPH Industry ExposureFull Holdings Details Similar ETFsVanEck Biotech ETFNASDAQ:BBHInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHProShares Ultra Nasdaq BiotechnologyNASDAQ:BIBPrincipal Healthcare Innovators ETFNASDAQ:BTECInstitutional OwnershipGSA Capital Partners LLPBought 8,744 shares on 5/3/2024Ownership: 0.324%Conservest Capital Advisors Inc.Sold 468 shares on 5/2/2024Ownership: 0.088%Mirae Asset Global Investments Co. Ltd.Bought 14,490 shares on 5/1/2024Ownership: 0.252%BNP Paribas Financial MarketsSold 99,998 shares on 5/1/2024Ownership: 0.031%Commonwealth Equity Services LLCBought 6,655 shares on 4/29/2024Ownership: 0.371%View All Institutional Transactions PPH ETF - Frequently Asked Questions How have PPH shares performed in 2024? VanEck Pharmaceutical ETF's stock was trading at $81.37 at the beginning of 2024. Since then, PPH shares have increased by 7.1% and is now trading at $87.11. View the best growth stocks for 2024 here. Are investors shorting VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 8,700 shares, a drop of 99.4% from the March 15th total of 1,570,000 shares. Based on an average daily trading volume, of 128,200 shares, the short-interest ratio is currently 0.1 days. View VanEck Pharmaceutical ETF's Short Interest. How often does VanEck Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF declared a dividend on Thursday, March 28th. Shareholders of record on Tuesday, April 2nd will be paid a dividend of $0.5328 per share on Friday, April 5th. The ex-dividend date of this dividend is Monday, April 1st. Read our dividend analysis for PPH. What does PPH invest in? VanEck Pharmaceutical ETF is a equity fund issued by Van Eck. PPH focuses on health care investments and follows the Market Vectors US Listed Pharmaceutical 25 Index. The fund's investments total to approximately $518.70 million assets under management. What stocks does VanEck Pharmaceutical ETF hold? PPH invests in 26 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Cencora (COR), McKesson (MCK), Haleon (HLN) and Sanofi (SNY). What is the management fee for VanEck Pharmaceutical ETF? VanEck Pharmaceutical ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for PPH is 0.35%. What is Bruce Gordon's approval rating as VanEck Pharmaceutical ETF's CEO? 38 employees have rated VanEck Pharmaceutical ETF Chief Executive Officer Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among the company's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Pharmaceutical ETF investors own include Bank of America (BAC), Alibaba Group (BABA), AeroVironment (AVAV), Activision Blizzard (ATVI), ARK Innovation ETF (ARKK), Applied Materials (AMAT), Applied Graphene Materials (AGM), Air Canada (AC) and Abbott Laboratories (ABT). Who are VanEck Pharmaceutical ETF's major shareholders? VanEck Pharmaceutical ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.37%), GSA Capital Partners LLP (0.32%), Raymond James Financial Services Advisors Inc. (0.30%), Mirae Asset Global Investments Co. Ltd. (0.25%), Aspiriant LLC (0.10%) and Conservest Capital Advisors Inc. (0.09%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PPH) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.